STOCK TITAN

Affimed - AFMD STOCK NEWS

Welcome to our dedicated page for Affimed news (Ticker: AFMD), a resource for investors and traders seeking the latest updates and insights on Affimed stock.

Affimed N.V. (Nasdaq: AFMD) is a clinical-stage biopharmaceutical leader pioneering targeted immuno-oncology therapies through its proprietary ROCK® platform. This page serves as the definitive source for Affimed news, offering investors and researchers timely updates on scientific advancements and corporate developments.

Key resources include: Press releases on clinical trial progress, regulatory milestones, and strategic partnerships; financial reports detailing earnings and R&D investments; and analyses of bispecific antibody innovations. Users gain streamlined access to Affimed's latest innate cell engager (ICE®) research and pipeline updates across hematologic and solid tumors.

Content highlights: Clinical trial results, FDA/EMA regulatory filings, collaboration announcements with biopharma partners, and presentations at major medical conferences. Bookmark this page to efficiently track Affimed's progress in advancing next-generation cancer immunotherapies.

Rhea-AI Summary

Affimed N.V. (Nasdaq: AFMD) announced a collaboration with Roche to explore AFM24, its innate cell engager, in combination with Roche’s PD-L1 inhibitor atezolizumab for treating patients with advanced solid tumors expressing EGFR. The Phase 1/2a clinical trial will assess safety and efficacy, funded and conducted by Affimed with Roche supplying atezolizumab. This partnership aims to leverage the potential synergistic effects of AFM24 and PD-(L)1 inhibition. Previous studies suggest promising safety and activity profiles for AFM24 in preclinical settings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.15%
Tags
none
-
Rhea-AI Summary

Affimed N.V. announced the completion of its public offering of 19,166,667 common shares at a price of $6.00 per share, raising $115 million in gross proceeds. This includes the underwriters' full exercise option for an additional 2,500,000 shares. The offering underlines Affimed's commitment to advancing its immuno-oncology pipeline, which includes therapies for hematologic and solid tumors. Despite the capital raised, potential risks associated with the offering and market conditions remain.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.13%
Tags
-
Rhea-AI Summary

Affimed N.V. (Nasdaq: AFMD) announced the pricing of a public offering of 16,666,667 common shares at $6.00 per share, aiming to raise approximately $94 million after underwriting discounts. The offering includes a 30-day over-allotment option for underwriters to purchase an additional 2,500,000 shares. The proceeds are expected to support the company's clinical-stage immuno-oncology initiatives. The offering is scheduled to close around January 15, 2021, subject to standard conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.76%
Tags
Rhea-AI Summary

Affimed N.V. (Nasdaq: AFMD) announced the commencement of an underwritten public offering of common shares on January 12, 2021. The offering is expected to include a 30-day over-allotment option for underwriters to purchase an additional 15% of shares sold. Jefferies, SVB Leerink, and Credit Suisse are serving as joint book-running managers. The offering is contingent on market conditions, and there is uncertainty surrounding its completion or specific terms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.76%
Tags
-
Rhea-AI Summary

Heidelberg, Germany, January 11, 2021 – Affimed N.V. (Nasdaq: AFMD) announced that CEO Dr. Adi Hoess will present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 7:30 a.m. EST. A live webcast of the presentation will be available on Affimed’s website for 30 days post-event. Affimed focuses on immuno-oncology, developing therapies like AFM13 for CD30-positive relapsed/refractory peripheral T cell lymphoma and AFM24 for advanced EGFR-expressing solid tumors. For details, visit Affimed’s investor site.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.62%
Tags
conferences
-
Rhea-AI Summary

Affimed N.V. (Nasdaq: AFMD) announced a debt financing agreement with Silicon Valley Bank, offering up to €25 million in term loans. The structure includes €10 million available at closing, and two additional tranches of €7.5 million, contingent on specific milestones. Interest is set at a minimum of 5.5%, with the loan maturing in November 2025. Proceeds will support research and development of Affimed's ICE® molecules and general working capital.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.62%
Tags
none
Rhea-AI Summary

Affimed N.V. (Nasdaq: AFMD) reported progress in its clinical studies for AFM13 and AFM24 as the company aims to advance its immuno-oncology pipeline. CEO Adi Hoess highlighted a robust cash position of approximately €147 million, enabling operations into H1 2023. Key updates include the AFM13-202 trial for CD30-positive T-cell lymphoma, which is ahead of schedule, and the AFM24-101 trial, now in the fourth dose cohort. The company anticipates regulatory submissions and continued clinical development, positioning it well for future growth and innovation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.78%
Tags
none
-
Rhea-AI Summary

Affimed N.V. (Nasdaq: AFMD) announced promising results for its AFM13 bispecific Innate Cell Engager, achieving a 42% Objective Response Rate (ORR) in heavily pretreated patients with relapsed or refractory CD30-positive lymphoma. The data presented at the 62nd American Society of Hematology Meeting highlighted that AFM13 was well tolerated, with evidence of NK cell activity and recruitment in patients. This development is significant given the high therapeutic need in this patient population, especially after brentuximab vedotin failure.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.46%
Tags
-
Rhea-AI Summary

Affimed N.V. (Nasdaq: AFMD) announced promising results from its Phase 1b study of AFM13 in combination with KEYTRUDA for relapsed/refractory Hodgkin lymphoma. The study showed a complete response (CR) rate of 46% and an objective response rate (ORR) of 88% at the recommended dose, significantly outperforming KEYTRUDA alone, which had a CR of 22.4% and an ORR of 69%. The treatment was reported as well-tolerated with manageable adverse effects. Results suggest AFM13 could enhance current therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.49%
Tags
none
Rhea-AI Summary

Affimed announced a partnership with Roivant Sciences, receiving $60 million upfront and potential future milestones worth up to $2 billion.

The company ended Q3 2020 with €97.3 million in cash and equivalents, projecting runway into H1 2023.

Total revenue for Q3 was €10.5 million, a significant increase from €2.1 million year-over-year, driven by the Genentech collaboration.

Net loss decreased to €6 million, or €0.07 per share, from €10.9 million, or €0.17 per share, in Q3 2019.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.14%
Tags
Affimed

Nasdaq:AFMD

AFMD Rankings

AFMD Stock Data

12.02M
15.48M
6.01%
23.83%
4.32%
Biotechnology
Healthcare
Link
Germany
Mannheim